Concepts (112)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colitis, Ulcerative | 6 | 2020 | 208 | 2.080 |
Why?
|
| Bacteroides | 2 | 2021 | 34 | 1.350 |
Why?
|
| Crohn Disease | 3 | 2022 | 283 | 1.250 |
Why?
|
| Colitis | 4 | 2021 | 152 | 1.050 |
Why?
|
| Colectomy | 3 | 2020 | 75 | 0.850 |
Why?
|
| Fecal Microbiota Transplantation | 3 | 2022 | 92 | 0.810 |
Why?
|
| Trinitrobenzenesulfonic Acid | 2 | 2021 | 21 | 0.780 |
Why?
|
| Colon | 2 | 2021 | 353 | 0.750 |
Why?
|
| Rett Syndrome | 1 | 2024 | 289 | 0.750 |
Why?
|
| Gastrointestinal Diseases | 1 | 2024 | 335 | 0.720 |
Why?
|
| Methotrexate | 1 | 2022 | 341 | 0.700 |
Why?
|
| Interleukins | 1 | 2021 | 116 | 0.690 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2021 | 314 | 0.620 |
Why?
|
| Dysbiosis | 1 | 2018 | 119 | 0.570 |
Why?
|
| Disease | 1 | 2018 | 130 | 0.560 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2017 | 54 | 0.560 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2022 | 387 | 0.540 |
Why?
|
| Inflammation | 2 | 2021 | 1402 | 0.540 |
Why?
|
| Feces | 3 | 2022 | 709 | 0.540 |
Why?
|
| Gastrointestinal Microbiome | 4 | 2021 | 675 | 0.530 |
Why?
|
| Lipase | 1 | 2016 | 88 | 0.510 |
Why?
|
| Immunosuppressive Agents | 2 | 2022 | 643 | 0.500 |
Why?
|
| Antimetabolites | 1 | 2014 | 32 | 0.460 |
Why?
|
| Mercaptopurine | 1 | 2014 | 71 | 0.460 |
Why?
|
| Allopurinol | 1 | 2014 | 70 | 0.440 |
Why?
|
| Child | 14 | 2024 | 24223 | 0.410 |
Why?
|
| Bifidobacterium | 2 | 2021 | 63 | 0.350 |
Why?
|
| Dextran Sulfate | 2 | 2021 | 46 | 0.350 |
Why?
|
| Adolescent | 8 | 2024 | 19095 | 0.300 |
Why?
|
| Phenotype | 1 | 2017 | 4221 | 0.290 |
Why?
|
| Clostridium Infections | 2 | 2022 | 233 | 0.280 |
Why?
|
| Brain | 1 | 2018 | 2946 | 0.270 |
Why?
|
| Child, Preschool | 6 | 2024 | 13880 | 0.260 |
Why?
|
| Humans | 19 | 2024 | 123152 | 0.230 |
Why?
|
| Disease Progression | 2 | 2020 | 2023 | 0.200 |
Why?
|
| Proton Pump Inhibitors | 1 | 2024 | 254 | 0.190 |
Why?
|
| Delayed Diagnosis | 2 | 2022 | 120 | 0.190 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2022 | 371 | 0.180 |
Why?
|
| Retrospective Studies | 5 | 2022 | 15998 | 0.180 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2022 | 227 | 0.180 |
Why?
|
| Dipeptides | 1 | 2021 | 56 | 0.180 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2021 | 121 | 0.170 |
Why?
|
| Goblet Cells | 1 | 2021 | 104 | 0.170 |
Why?
|
| Serotonin | 1 | 2020 | 222 | 0.160 |
Why?
|
| Bacteria | 2 | 2022 | 482 | 0.160 |
Why?
|
| Intestinal Mucosa | 2 | 2021 | 774 | 0.160 |
Why?
|
| Cytokines | 2 | 2021 | 1283 | 0.150 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2018 | 10 | 0.150 |
Why?
|
| Dendritic Cells | 1 | 2021 | 402 | 0.150 |
Why?
|
| Prevalence | 1 | 2024 | 2405 | 0.150 |
Why?
|
| Probiotics | 1 | 2021 | 208 | 0.150 |
Why?
|
| Granuloma | 1 | 2018 | 67 | 0.150 |
Why?
|
| Case-Control Studies | 1 | 2024 | 3251 | 0.140 |
Why?
|
| Parents | 1 | 2024 | 1023 | 0.140 |
Why?
|
| Immunocompromised Host | 1 | 2019 | 300 | 0.140 |
Why?
|
| Infant, Newborn | 2 | 2022 | 8103 | 0.140 |
Why?
|
| Gastrointestinal Tract | 1 | 2019 | 208 | 0.140 |
Why?
|
| Intestines | 1 | 2021 | 571 | 0.140 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2017 | 49 | 0.140 |
Why?
|
| Survival Analysis | 1 | 2019 | 1469 | 0.120 |
Why?
|
| Salmonella | 1 | 2015 | 28 | 0.120 |
Why?
|
| Animals | 6 | 2022 | 33720 | 0.120 |
Why?
|
| Infant | 2 | 2022 | 12339 | 0.120 |
Why?
|
| Salmonella Infections | 1 | 2015 | 31 | 0.120 |
Why?
|
| Guanine Nucleotides | 1 | 2014 | 15 | 0.120 |
Why?
|
| Thionucleotides | 1 | 2014 | 19 | 0.120 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 3660 | 0.120 |
Why?
|
| Pancreatitis | 1 | 2016 | 130 | 0.120 |
Why?
|
| Mice | 5 | 2022 | 17486 | 0.110 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2015 | 93 | 0.110 |
Why?
|
| Hospitalization | 1 | 2022 | 1733 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3379 | 0.110 |
Why?
|
| Female | 7 | 2024 | 65442 | 0.110 |
Why?
|
| Male | 8 | 2021 | 60038 | 0.100 |
Why?
|
| Heart Transplantation | 1 | 2019 | 854 | 0.100 |
Why?
|
| Acute Disease | 1 | 2016 | 1090 | 0.100 |
Why?
|
| Germ-Free Life | 2 | 2022 | 59 | 0.100 |
Why?
|
| Young Adult | 1 | 2024 | 8865 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 1149 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 5046 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 1873 | 0.090 |
Why?
|
| United States | 2 | 2022 | 10629 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 4345 | 0.080 |
Why?
|
| Organoids | 2 | 2022 | 276 | 0.080 |
Why?
|
| Risk Factors | 2 | 2020 | 10010 | 0.080 |
Why?
|
| Biomarkers | 1 | 2017 | 2942 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 4268 | 0.080 |
Why?
|
| Prognosis | 1 | 2017 | 4505 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2019 | 3011 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2022 | 12116 | 0.070 |
Why?
|
| Recurrence | 2 | 2022 | 1422 | 0.070 |
Why?
|
| Texas | 1 | 2015 | 3547 | 0.070 |
Why?
|
| Adult | 1 | 2024 | 29032 | 0.060 |
Why?
|
| Chromatography, Liquid | 1 | 2022 | 191 | 0.050 |
Why?
|
| Seroconversion | 1 | 2021 | 14 | 0.050 |
Why?
|
| Mammals | 1 | 2022 | 262 | 0.050 |
Why?
|
| Morbidity | 1 | 2022 | 240 | 0.050 |
Why?
|
| Mucin-2 | 1 | 2021 | 40 | 0.050 |
Why?
|
| Enterochromaffin Cells | 1 | 2020 | 10 | 0.050 |
Why?
|
| Receptors, Serotonin | 1 | 2020 | 42 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2021 | 81 | 0.040 |
Why?
|
| Acetates | 1 | 2020 | 70 | 0.040 |
Why?
|
| Minority Groups | 1 | 2022 | 250 | 0.040 |
Why?
|
| Metabolomics | 1 | 2022 | 409 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 287 | 0.040 |
Why?
|
| Models, Animal | 1 | 2020 | 464 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2021 | 1002 | 0.040 |
Why?
|
| Behavior, Animal | 1 | 2020 | 477 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1134 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2017 | 239 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2022 | 6028 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 4704 | 0.020 |
Why?
|